Literature DB >> 33647611

Low doses of zeolitic imidazolate framework-8 nanoparticles alter the actin organization and contractility of vascular smooth muscle cells.

Divya Kota1, Lin Kang1, Alex Rickel2, Jinyuan Liu1, Steve Smith1, Zhongkui Hong3, Congzhou Wang4.   

Abstract

Zeolitic imidazolate framework-8 (ZIF-8) nanoparticles have emerged as a promising platform for drug delivery and controlled release. Considering most ZIF-8 nanoparticle drug carriers are designed to be administered intravenously, and thus would directly contact vascular smooth muscle cells (VSMCs) in many circumstances, the potential interactions of ZIF-8 nanoparticles with VSMCs require investigation. Here, the effects of low doses of ZIF-8 nanoparticles on VSMC morphology, actin organization, and contractility are investigated. Two nanoscale imaging tools, atomic force microscopy, and direct stochastic optical reconstruction microscopy, show that even at the concentrations (12.5 and 25 µg/ml) that were deemed "safe" by conventional biochemical cell assays (MTT and LDH assays), ZIF-8 nanoparticles can still cause changes in cell morphology and actin cytoskeleton organization at the cell apical and basal surfaces. These cytoskeletal structural changes impair the contractility function of VSMCs in response to Angiotensin II, a classic vasoconstrictor. Based on intracellular zinc and actin polymerization assays, we conclude that the increased intracellular Zn2+ concentration due to the uptake and dissociation of ZIF-8 nanoparticles could cause the actin cytoskeleton dis-organization, as the elevated Zn2+ directly disrupts the actin assembly process, leading to altered actin organization such as branches and networks. Since the VSMC phenotype change and loss of contractility are fundamental to the development of atherosclerosis and related cardiovascular diseases, it is worth noting that these low doses of ZIF-8 nanoparticles administered intravenously could still be a safety concern in terms of cardiovascular risks. Moving forward, it is imperative to re-consider the "safe" nanoparticle dosages determined by biochemical cell assays alone, and take into account the impact of these nanoparticles on the biophysical characteristics of VSMCs, including changes in the actin cytoskeleton and cell morphology.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Actin cytoskeleton; Cell morphology; Contractility; Vascular smooth muscle cells; Zeolitic imidazolate framework-8 nanoparticles

Mesh:

Substances:

Year:  2021        PMID: 33647611      PMCID: PMC8144069          DOI: 10.1016/j.jhazmat.2021.125514

Source DB:  PubMed          Journal:  J Hazard Mater        ISSN: 0304-3894            Impact factor:   14.224


  72 in total

1.  Enhanced Stability and Controlled Delivery of MOF-Encapsulated Vaccines and Their Immunogenic Response In Vivo.

Authors:  Michael A Luzuriaga; Raymond P Welch; Madushani Dharmarwardana; Candace E Benjamin; Shaobo Li; Arezoo Shahrivarkevishahi; Sarah Popal; Lana H Tuong; Chayton T Creswell; Jeremiah J Gassensmith
Journal:  ACS Appl Mater Interfaces       Date:  2019-03-01       Impact factor: 9.229

2.  Gold Nanoparticles Induced Endothelial Leakiness Depends on Particle Size and Endothelial Cell Origin.

Authors:  Magdiel I Setyawati; Chor Yong Tay; Boon Huat Bay; David T Leong
Journal:  ACS Nano       Date:  2017-04-20       Impact factor: 15.881

3.  Interference of Steroidogenesis by Gold Nanorod Core/Silver Shell Nanostructures: Implications for Reproductive Toxicity of Silver Nanomaterials.

Authors:  Xiumei Jiang; Liming Wang; Yinglu Ji; Jinglong Tang; Xin Tian; Mingjing Cao; Jingxuan Li; Shuying Bi; Xiaochun Wu; Chunying Chen; Jun-Jie Yin
Journal:  Small       Date:  2016-12-23       Impact factor: 13.281

4.  Atomic force microscopy reveals drebrin induced remodeling of f-actin with subnanometer resolution.

Authors:  Shivani Sharma; Elena E Grintsevich; Martin L Phillips; Emil Reisler; James K Gimzewski
Journal:  Nano Lett       Date:  2010-12-22       Impact factor: 11.189

Review 5.  Metal-Organic Framework (MOF)-Based Drug/Cargo Delivery and Cancer Therapy.

Authors:  Ming-Xue Wu; Ying-Wei Yang
Journal:  Adv Mater       Date:  2017-03-29       Impact factor: 30.849

6.  Biomimetic mineralization of metal-organic frameworks as protective coatings for biomacromolecules.

Authors:  Kang Liang; Raffaele Ricco; Cara M Doherty; Mark J Styles; Stephen Bell; Nigel Kirby; Stephen Mudie; David Haylock; Anita J Hill; Christian J Doonan; Paolo Falcaro
Journal:  Nat Commun       Date:  2015-06-04       Impact factor: 14.919

7.  Phenotypic modulation of primary vascular smooth muscle cells by short-term culture on micropatterned substrate.

Authors:  Soyoung Chang; Seungjeong Song; Jungsul Lee; Jonghee Yoon; Junseong Park; Sungyoung Choi; Je-Kyun Park; Kyungsun Choi; Chulhee Choi
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 8.  Bioengineering of Metal-organic Frameworks for Nanomedicine.

Authors:  Yuan Liu; Yanli Zhao; Xiaoyuan Chen
Journal:  Theranostics       Date:  2019-05-18       Impact factor: 11.556

9.  Measurement and analysis of in vitro actin polymerization.

Authors:  Lynda K Doolittle; Michael K Rosen; Shae B Padrick
Journal:  Methods Mol Biol       Date:  2013

10.  Curcumin encapsulated zeolitic imidazolate frameworks as stimuli responsive drug delivery system and their interaction with biomimetic environment.

Authors:  Ashish Tiwari; Ashutosh Singh; Neha Garg; Jaspreet K Randhawa
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

View more
  2 in total

1.  Targeting cancer cell adhesion molecule, CD146, with low-dose gold nanorods and mild hyperthermia disrupts actin cytoskeleton and cancer cell migration.

Authors:  Jinyuan Liu; Lin Kang; Ishara Ratnayake; Phil Ahrenkiel; Steve Smith; Congzhou Wang
Journal:  J Colloid Interface Sci       Date:  2021-05-26       Impact factor: 8.128

Review 2.  Photodynamic and Photothermal Therapy of Hepatocellular Carcinoma.

Authors:  Zhe Fan; Chengjun Zhuang; Shuang Wang; Yewei Zhang
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.